drugset / Trial / NCT00452478
Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to patients on haemodialysis works as well as other treatments currently used to lower blood phosphorus levels.
Timeline
- Start
- 2007-05-22
- Primary completion
- 2007-12-10
- Completion
- 2007-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanthanum Carbonate | Other / unclassified | 2250 mg | Oral |